Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 40Neoplasms 8Prostatic Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Quality of Life 1Neoplasms by Site 1Multiple Endocrine Neoplasia Type 1 1Hot Flashes 1Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Gynecomastia 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Breast Diseases 1Breast Cancer Subjects 1Breast Cancer Metastatic 1Breast Cancer Female 1Bone Density 1Advanced Metastatic Breast Cancer 1Advanced Cancer 1

Interventions

Tamoxifen 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Breast Cancer Subjects × Tamoxifen × Clear all
NCT06449027 2025-10-01

Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 3 Active not recruiting
211 enrolled
Breast

Breast Cancer Subjects

Data powered by HemOnc (CC BY 4.0) Colophon âš¡